Zhaoke Ophthalmology Limited (HKG:6622)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.430
+0.040 (1.18%)
At close: Mar 10, 2026
63.33%
Market Cap 1.86B
Revenue (ttm) 38.74M
Net Income (ttm) -304.97M
Shares Out 548.75M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 487,708
Average Volume 619,790
Open 3.500
Previous Close 3.390
Day's Range 3.370 - 3.570
52-Week Range 1.300 - 4.600
Beta 1.21
RSI 52.89
Earnings Date Mar 24, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, Hong Kong, and internationally. It develops various drugs that cover ophthalmic indications, including dry eye disease, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 270
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6622
Full Company Profile

Financial Performance

In 2024, Zhaoke Ophthalmology's revenue was 69.32 million, an increase of 269.73% compared to the previous year's 18.75 million. Losses were -237.49 million, -38.32% less than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.